Characteristics of persons who complied with and failed to comply with annual ivermectin treatment-Reference-Cited by-同舟云学术

Characteristics of persons who complied with and failed to comply with annual ivermectin treatment

Published:2012-05-11 Issue:7 Volume:17 Page:920-930
ISSN:1360-2276
Container-title:Tropical Medicine & International Health
language:en
Short-container-title:

Author:

Brieger William R.,Okeibunor Joseph C.,Abiose Adenike O.,Ndyomugyenyi Richard,Wanji Samuel,Elhassan Elizabeth,Amazigo Uche V.

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Parasitology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-3156.2012.03007.x/fullpdf

Reference41 articles.

1. African Programme for Onchocerciasis Control 2004 Year 2004 progress report of WHO/APOC http://www.apoc.bf/en/download.htm

2. African Programme for Onchocerciasis Control 2005 Report of the 20th session of the Technical Consultative Committee (TCC) Ouagadougou, 14-19 March 2005 http://www.apoc.bf/en/download.htm

3. African Programme for Onchocerciasis Control 2006 Special meeting on sustainability of CDTI: final communiqué and recommendations, Ouagadougou, 2-5 February 2006 http://www.apoc.bf/en/download.htm

4. African Programme for Onchocerciasis Control 2007 Community Directed Treatment with Ivermectin (CDTI): a pratical guide for trainers of Community Directed Distributors (CDDs http://www.apoc.bf/en/CDTI

5. Community-perceived benefits of ivermectin treatment in northeastern Nigeria;Akogun;Social Science and Medicine,2000

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mass drug administration coverage and determinants of drug uptake for elimination of Onchocerciasis in Ulanga District;2024-05-17

2. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia;Parasites & Vectors;2024-03-15

3. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial;Malaria Journal;2024-02-22

4. Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study;BMC Infectious Diseases;2023-11-16

5. Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial;2023-11-15